Cytovia Therapeutics appoints CFO, chief product officer
Cytovia Therapeutics
Luca Scavo is now chief financial officer at Cytovia Therapeutics.
Cytovia Therapeutics, a Florida company with research-and-development operations in Natick, has named a chief financial officer and a chief product officer, as the company advances towards clinical trials and prepares to go public.
The company, which focuses on empowering natural killer cells to fight cancer through multispecific antibodies and stem cell engineering, has named Luca Scavo as chief financial officer, and James Priour as chief product officer, both effective immediately.
Scavo, a certified public accountant with an MBA from Instituto de Empresa in Madrid, Spain, joins Cytovia from Cambridge-based Evelo Biosciences, Inc., where he was also chief financial officer. Prior to that, he was senior vice president and chief financial officer of Roche Diagnostics North America, headquartered in Indiana. He was also chief financial officer of AstraZeneca Spain and held global leadership roles in the Roche organization for more than 20 years.
Priour has more than 30 years of leadership experience in drug development, portfolio strategy, commercialization, strategic partnership, and alliance management. He has been chief commercial officer at clinical-stage biopharmaceutical company Zymeworks, Inc., headquartered in Canada, since 2020. Before that, he was in Southern California at Amgen corporate headquarters, where he was global lead for a medication approved for relapsed or refractory multiple myeloma. He was quickly appointed global product general manager for the entire myeloma treatment franchise.
Also an MBA from the NEOMA Business School in France, Priour’s work has brought him all around the world, from the U.S. to France, Australia and New Zealand, Hungary, Belgium, and Luxemburg.
WBJ Web Partners
Most Recent
Most Recent
0 Comments